Skip to main content
. Author manuscript; available in PMC: 2011 Dec 20.
Published in final edited form as: Gene Ther. 2010 Mar 11;17(6):805–810. doi: 10.1038/gt.2010.20

Figure 3. Mice treated with bPΔ6-hPAP show tumor reduction and increased survival.

Figure 3

C57/BL6 mice were implanted subcutaneously in the flanks with TRAMP-C2 cells (5×106/mouse). Once tumors were established (50-100 mm3) mice (N=8) were randomized and treated four times with 1×107 pfu of bPΔ6-empty, bPΔ6-mPAP, bPΔ6-hPAP or PBS over a period of 10 days by direct intra-tumoral inoculation. Tumor volumes were monitored using calipers and calculated with the formula v = [(length) × (width2)] / 2. Mice were sacrificed when tumors reached 1000 mm3. Animals treated with bPΔ6-hPAP showed a significant reduction in tumor volume (p=0.002, PBS vs hPAP: p=0.04, Empty vs hPAP: p=0.03, mPAP vs hPAP) (A) and a significant increase in survival (B) when compared with the bPΔ6-mPAP (p=0.01), bPΔ6-empty (0.01) or PBS (p=0.0008) groups. Analysis of tumor volumes (day 24, Student’s t-test) and survival (log-rank test) were performed with GraphPad Prism v.4 (San Diego, CA).